Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 29, 2019

Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis

  • Sara Baldelli EMAIL logo , Marta Fusi , Valeria Cozzi , Emilio Clementi , Nadia Maria Luisa Faelli , Maria Russo , Carla Colombo and Dario Cattaneo

Corresponding author: Sara Baldelli, Chem.D, Unit of Clinical Pharmacology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, 20157 Milan, Italy, Phone: 00390250319619, Fax: 00390250119646

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015;61:1558–65.10.1093/cid/civ571Search in Google Scholar PubMed

2. Jović Z, Janković SM, Ružić Zečević D, Milovanović D, Stefanović S, Folić M, et al. Clinical pharmacokinetics of second-generation triazoles for the treatment of invasive aspergillosis and candidiasis. Eur J Drug Metab Pharmacokinet 2019;44:139–57.10.1007/s13318-018-0513-7Search in Google Scholar PubMed

3. Desai A, Yamazaki T, Dietz AJ, Kowalski D, Lademacher C, Pearlman H, et al. Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects. Clin Pharmacol Drug Dev 2017;6:86–92.10.1002/cpdd.283Search in Google Scholar PubMed PubMed Central

4. Andes DR, Ghannoum MA, Mukherjee PK, Kovanda LL, Lu Q, Jones ME, et al. Outcomes by MIC values for patients treated with isavuconazole or voriconazole for invasive aspergillosis in the phase 3 SECURE and VITAL trials. Antimicrob Agents Ch 2018;63. pii: e01634-18.10.1128/AAC.01634-18Search in Google Scholar PubMed PubMed Central

5. Rivosecchi RM, Samanta P, Demehin M, Nguyen MH. Pharmacokinetics of azole antifungals in cystic fibrosis. Mycopathologia 2018;183:139–50.10.1007/s11046-017-0189-6Search in Google Scholar PubMed

6. Billaud EM, Guillemain R, Berge M, Amrein C, Lefeuvre S, Louët AL, et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med Mycol 2010;48(Suppl 1):S52–9.10.3109/13693786.2010.505203Search in Google Scholar PubMed

7. Kabulski GM, MacVane SH. Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation. Transpl Infect Dis 2018;20:e12878.10.1111/tid.12878Search in Google Scholar PubMed

8. Cozzi V, Baldelli S, Castoldi S, Clementi E, Cattaneo D. Development and validation of a chromatographic ultraviolet method for the quantification of isavuconazole in human plasma samples. Ther Drug Monit 2018;40:512–4.10.1097/FTD.0000000000000523Search in Google Scholar PubMed

9. Arsiè E, Piconi S, Iavarone M, Cozzi V, Lampertico P, Cattaneo D. High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis. Eur J Clin Pharmacol 2018;74:1089–90.10.1007/s00228-018-2462-0Search in Google Scholar PubMed

Received: 2019-02-19
Accepted: 2019-05-01
Published Online: 2019-05-29
Published in Print: 2019-10-25

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 1.6.2023 from
Scroll to top button